







GDF-15 as a biomarker of HIV reservoir size in ART-treated PLWH

Stéphane Isnard, PhD

FRQ-S CIHR/CTN Post Doctoral fellow Dr Jean-Pierre Routy's lab Montréal, Canada


No conflict of interest

Background

GDF-15 = Growth Differentiation Factor 15

Atypical member of the TGF- β family

- Regulates bodyweight through a peripheral brain axis: speci receptor GFRAL in the brainstem.
- Also a marker of mitochondrial stress induced by hypoxia, mitochondrial DNA damage, reticulum endoplasmic stress, etc.
- Circulating levels of GDF-15 are elevated in people with:
 - \rightarrow Aging
 - → Cardiovascular diseases
 - → Sepsis
 - → Cancer
 - → Asthma
 - → Severe COVID-19




Fujita, Arch Biochem Biophys2020

Objectives: Are circulating GDF-15 levels different in People living with HIV compared to uninfected controls?

What mechanisms influence GDF-15 levels in PLWH?


Plasma levels of GDF-15 in PLWH are linked with age in ART-treated PLWH




Plasma GDF-15 levels were higher in ART-treated PLWH compared to uninfected controls. GDF-15 levels were associated with age. Sex and type or class of ART had no influence on GDF-15 levels.

GDF-15 levels are associated with reservoir size and risk of comorbidities, independently of inflammation

In ART-treated PLWH:



No association between GDF-15 levels and **inflammation** markers including inflammatory cytokines, gut damage and microbial translocation markers.



Association with the marker of non-AIDS comorbidities suPAR (soluble urokinase plasminogen activator receptor)

(see Hoenigl et al. *CID* 2019) independently of sex and class of ART

<u>Conclusion</u>: Circulating GDF-15 levels were associated with **HIV reservoir size** and **non-AIDS comorbidity** marker suPAR, <u>independently of age, sex, and inflammation markers</u>.

In vitro stimulation experiment confirmed that inflammatory stimuli do not induce GDF-15 in blood samples (data not shown).

<u>Future directions</u>: Molecular mechanism and confirmation of the role of GDF-15 in non-AIDS comorbidities Is GDF-15 a marker of accelerated aging in ART-treated PLWH?

Team Jean-Pierre Routy

Dr Jean-Pierre Routy Dr Léna Royston John Lin Brandon Fombuena Dr Franck P Dupuy Dr Jing Ouyang Dr Xiaorong Peng

Simeng Bu



Rayoun Ramendra Josée Girouard Angie Massicotte Cezar Iovi

Acknowledgment

CVIS

Drs C Costiniuk,
B Lebouché, A de
Pokomandy, J Szabo,
M Teltscher, J Cox,
E Beauchamp, LP Haraoui,
M Klein, Nurses and staff



Team Dr P Ancuta
Team Dr N Chomont
Team Dr C Tremblay
Team Dr M Durand,
Dr C Chartrand-Lefebvre

All study participants

Stephane.isnard@mail.mcgill.ca

Montreal Primary HIV-infection cohort Canadian HIV and Aging Cohort











